Holen Sie sich die Stockscreener-App
4.60
1.91%
-0.10
Handel nachbörslich:
4.69
0.09
+1.96%
Schlusskurs vom Vortag:
$4.70
Offen:
$4.6
24-Stunden-Volumen:
550.33K
Relative Volume:
0.55
Marktkapitalisierung:
$243.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.14M
KGV:
-5.00
EPS:
-0.92
Netto-Cashflow:
$-12.64M
1W Leistung:
+1.99%
1M Leistung:
-19.41%
6M Leistung:
+55.22%
1J Leistung:
+125.98%
1-Tages-Spanne:
$4.54
$4.83
1-Wochen-Bereich:
$4.40
$5.09
52-Wochen-Spanne:
$1.34
$7.73
Immix Biopharma Inc Stock (IMMX) Company Profile
Firmenname
Immix Biopharma Inc
Sektor
Branche
Telefon
(888) 958-1084
Adresse
11400 WEST OLYMPIC BLVD., LOS ANGELES
Vergleichen Sie IMMX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
4.60 | 248.89M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.98 | 111.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.95 | 77.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
809.42 | 49.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
355.53 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
334.28 | 37.42B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Market Recap: Why Immix Biopharma Inc. stock remains undervaluedQuarterly Market Summary & Comprehensive Market Scan Reports - bollywoodhelpline.com
Is Immix Biopharma Inc stock a good pick for beginnersMarket Trend Report & Safe Entry Point Identification - baoquankhu1.vn
Published on: 2026-01-13 06:33:30 - Улправда
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities - Benzinga
Immix Biopharma (NASDAQ:IMMX) Downgraded to Sell Rating by Wall Street Zen - Defense World
Immix Biopharma to offer and sell up to $750 million in securitiesSEC filing - marketscreener.com
Immix Biopharma — NXC-201’s path to BLA submission - Smartkarma
Why analysts upgrade Immix Biopharma Inc. stock2025 Winners & Losers & Low Risk High Win Rate Picks - ulpravda.ru
Why Immix Biopharma Inc. stock is a must watch in 2025July 2025 Decliners & High Accuracy Investment Entry Signals - Улправда
Why Immix Biopharma Inc. stock remains undervalued2025 Earnings Impact & High Return Trade Guides - Улправда
What technical charts say about Immix Biopharma Inc. stock2025 Support & Resistance & Weekly Watchlist for Hot Stocks - ulpravda.ru
What momentum indicators show for Immix Biopharma Inc. stockRate Hike & Accurate Intraday Trading Signals - ulpravda.ru
Fed Watch: Why analysts upgrade Immix Biopharma Inc stockWeekly Trading Summary & Risk Adjusted Swing Trade Ideas - Bộ Nội Vụ
Swing Trade: Can Immix Biopharma Inc stock surprise with earnings upsidePortfolio Update Report & Consistent Profit Alerts - moha.gov.vn
Why Immix Biopharma Inc stock remains undervaluedJuly 2025 Patterns & Fast Exit and Entry Trade Guides - moha.gov.vn
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 27.5% in December - MarketBeat
Immix Biopharma (NASDAQ:IMMX) & Athira Pharma (NASDAQ:ATHA) Critical Survey - Defense World
Immix Biopharma (IMMX) price target increased by 50.00% to 12.24 - MSN
Immix Biopharma (IMMX) Price Target Increased by 50.00% to 12.24 - Nasdaq
Is Immix Biopharma Inc. stock resilient to inflation2025 Growth vs Value & Accurate Buy Signal Notifications - Улправда
Is Immix Biopharma Inc. stock positioned well for digital economyTake Profit & Expert Curated Trade Setups - Улправда
Why Immix Biopharma Inc. stock remains on buy listsPortfolio Return Report & Precise Swing Trade Entry Alerts - DonanımHaber
Is Immix Biopharma Inc. stock positioned for long term growth2025 Retail Activity & Free Risk Controlled Daily Trade Plans - DonanımHaber
What hedge fund activity signals for Immix Biopharma Inc. stock2025 Sector Review & Free Risk Controlled Daily Trade Plans - ulpravda.ru
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - Defense World
Immix Biopharma Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Minimal Risk High Reward - earlytimes.in
Trendlines Converge — Decision Point for Tirupati Starch and Chemicals LimitedTake Profit Strategies & Compound Your Gains With Quality Stocks - earlytimes.in
Immix Biopharma FY2025 EPS Forecast Boosted by HC Wainwright - Defense World
Aug Summary: Will Immix Biopharma Inc stock benefit from infrastructure spending2025 Macro Impact & Verified Entry Point Detection - moha.gov.vn
FY2025 EPS Estimates for Immix Biopharma Lifted by Analyst - MarketBeat
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition (IMMX) - Seeking Alpha
Immix Biopharma Stock Surges 70%, With A 6-Day Winning Spree - Trefis
Immix Biopharma CFO Gabriel Morris buys $5k in shares By Investing.com - Investing.com Canada
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares By Investing.com - Investing.com Canada
Immix Biopharma CFO Gabriel Morris buys $5k in shares - Investing.com
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares - Investing.com
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright - Investing.com Australia
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright By Investing.com - Investing.com South Africa
IMMX Analyst Rating Update: HC Wainwright Raises Price Target to - GuruFocus
Immix Biopharma closes $93.7 million public offering By Investing.com - Investing.com Canada
Immix Biopharma closes $93.7 million public offering - Investing.com
Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants - marketscreener.com
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Immix Biopharma prices $100M equity raise via common stock and warrant offering - MSN
Taking the lead: Immix Biopharma Inc (IMMX) - setenews.com
Finanzdaten der Immix Biopharma Inc-Aktie (IMMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.60%
1.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):